All Articles

Post-hoc analytical data of the randomized phase 3 SANET-ep trial indicate that multitargeted tyrosine kinase inhibitor surufatinib therapy was associated with maintenance of health-related quality of life (HRQoL) in previously treated patients with progressive, well-differentiated, advanced extrapancreatic neuroendocrine tumors (NETs).

Real-world clinical practice data indicate that telotristat ethyl (TE) use in patients with progressive neuroendocrine tumors (NETs) may provide clinical benefit in terms of improvements in carcinoid syndrome (CS) symptoms, functional status, and weight.

Safety analysis data of concomitant telotristat ethyl (TE) plus peptide receptor radionuclide therapy (PRRT) in patients with metastatic/nonresectable neuroendocrine tumors (NETs) and carcinoid syndrome diarrhea (CSD) indicate that the safety profile of combination treatment was consistent with individual TE and PRRT therapies.

Results of the TELEPRO-II study showed that telotristat ethyl (TE) treatment resulted in significant, clinically relevant improvements across carcinoid syndrome (CS) symptoms in a real-world setting.

Findings of a retrospective analysis suggest that patients with well-differentiated metastatic/unresectable grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may derive modest progression-free survival (PFS) benefit with somatostatin analog (SSA) monotherapy.

Findings of a comparative real-world analysis of long-acting somatostatin analogs (SSAs) indicate that lanreotide was associated with lower injection burden, use of rescue medications, and cost.

Results of the randomized, open-label phase 2 Australasian Gastrointestinal Trials Group CONTROL NET study indicate that capecitabine/temozolomide (CAPTEM) plus ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy (PPRT) combination treatment was active and well-tolerated compared with CAPTEM or PPRT alone in patients with pancreatic neuroendocrine tumors (pNETs) and updated midgut neuroendocrine tumors (mNETs).

Real-world data from a retrospective analysis of octreotide long-acting release (LAR) dosing patterns on treatment persistence in patients with symptomatic metastatic neuroendocrine tumors (NETs) indicate that physician experience and treatment at tertiary centers has a significant impact on dose selection and treatment persistence.

Findings of a comparative retrospective analysis indicate that first-line octreotide long-acting release (LAR) and lanreotide treatment was associated with similar progression-free survival (PFS) and biochemical response in patients with metastatic, well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Results of the CLARINET FORTE trial showed that lanreotide autogel (LAN) 120 mg at escalating dosing frequency (every 14 days) was associated with promising progression-free survival (PFS) benefit and no new safety issues in patients with progressive pancreatic or midgut neuroendocrine tumors (NETs).